Mortality after clinical management of aids-associated cryptococcal meningitis in Kenya

East African Medical Journal

Volumn 91, Issue 5, 2014, Pages 145-151

  Baldassarre, R ^a   Mdodo, R ^b   Omonge, E ^c   Jaoko, W ^c   Baddley, J ^d   Pappas, P ^e   Kempf, Mirjam Colette ^e   Aban, I ^e   Odera, S ^f   Suleh, A ^g   Jolly, P E ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c KENYATTA NATIONAL HOSPITAL   (Kenya)

^d School of Medicine

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f UNIVERSITY OF NAIROBI   (Kenya)

^g Mbagathi District Hospital   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CD4 LYMPHOCYTE COUNT; COMORBIDITY; COMPLICATION; FEMALE; HOSPITAL MORTALITY; HUMAN; IMMUNOLOGY; KENYA; MALE; MENINGITIS, CRYPTOCOCCAL; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; YOUNG ADULT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COMORBIDITY; FEMALE; HOSPITAL MORTALITY; HUMANS; KENYA; MALE; MENINGITIS, CRYPTOCOCCAL; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84999185251     PISSN: 0012835X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Harrison B. T. Cryptococcal meningitis. Br. Med. Bull. 72: 99-118.
2. Park, B. J., Wannemuehler, K., AMarston, B. J., et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 23: 525-530.
3. Okongo, M., Morgan, D., Mayanja, B. and Ross, A. Causes of death in a rural, population-based human immunodeficiency virus type 1 (HIV-1) natural history cohort in Uganda. Int. J. Epidemiol. 27:698-702.
4. French, N., Gray, K., Watera, C., et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS. 16: 1031-1038.
5. Schaars, C. F., Meintjes, G. A., Morroni, C., et al. Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of luconazole. BMC Infect Dis. 2006, 6: 118.
6. National AIDS and STI Control Programme, Ministry of Health, Kenya. July 2008. Kenya AIDS Indicator Survey 2012: Preliminary Report. Nairobi, NASCOP; 2013.
7. McCarthy, K. and Meintjes, G. Guidelines for the Prevention, Diagnosis and Management of Cryptococcal Meningitis and Disseminated Cryptococcosis in HIV Infected Patients. Southern African Journal of HIV Medicine 2007, Spring: 25-35.
8. Jarvis, J. and Harrison, T. S. HIV-associated cryptococcal meningitis. AIDS. 21:2119-2129.
9. Hakim, J. G., Gangaidzo, I. T., Heyderman, R. S., et al. Impact of HIV infection on meningitis in Harare, Zimbabwe: A prospective study of406 predominantly adult patients. AIDS. 14: 1401-1407.
10. Kambugu, A. D., Meya, D. B., Rhein, J. O., et al. Outcomes of cryptocccal meningitis in Uganda before and after the availability of highly active antiretroviral therapy Clin. Infect. Dis. 46: 1694-1701.
11. Meya, D. B., Manabe, Y. C., Castelnuovo, B., et al. Cost Effectiveness of Serum Cryptococcal Antigen Screening to Prevent Deaths among HIV-Infected Persons with a CD4+ Cell Count ≤100 Cells/μL Who Start HIV Therapy in Resource-Limited Settings. Clin. Infect. Dis. 2010, 51: 448-455.
12. Bicanic, T., Meintjes, G., Wood. R., et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral experienced patients treated with amphotericin B or fluconazole. Clin. Infect. Dis. 45: 76-80.
13. Longley, N., Muzoora, C., Taseera, K., et al. Doseresponse effect of high dose fluconazole for HIV associated cryptococcal meningitis in Southwest Uganda. Clin. Infect. Dis. 47: 1556-1561.
14. Coker, R. J., Tomlinson, D. R., Parkin, J., et al. Interaction between fluconazole and rifampicin [letter]. BMJ. 301: 818.
15. Panomvana, N.A. and Ayudhya, D., Thanompuangseree, N. and Tansuphaswadikul, S. Effect of rifampicin on the pharmacokinetics of fluconazole in patients with AIDS. Clin. Pharmacokinet. 43: 725-732.
16. Bicanic, T., Meintjes, G., Wood, R., et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral experienced patients treated with amphotericin B or fluconazole. Clin. Infect. Dis. 45: 76-80.
17. Bicanic, T., Meintjes, G., Rebe, K., et al. Immune reconstitution inflammatory syndrome in HIV associated cryptococcal meningitis: A prospective study. J. Acquir. Immune. Defic. Syndr. 51: 130-134.
18. Bii, C. C., K. Makimura, S. Abe, H. et al. Antifungal drug susceptibility of Cryptococcus neoformans from clinical sources in Nairobi, Kenya. Mycoses. 50: 25-30.